Although intracellular iodine is rapidly released, resulting in limited retention time of the radioiodide within cells, NIS-based radioiodide therapy has demonstrated therapeutic efficacy in vitro and in partial tumor xenograft studies. The gene discussed is SLC5A5; the disease is neoplasm.